NCT01677884已完成2 期
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Efficiency of treatment based on objective response rate
研究概览
简要总结
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Liver metastases of colon cancer or rectal predominant (histological evidence obtained on the primary tumor or liver metastases)
- •Isolated (no extra-hepatic metastasis, primary tumor resected)
- •No access to curative hepatectomy (R0 resection foreseeable or not leaving less than 30% residual non-tumor liver normally vascularized), or requiring complex hepatectomy, very large (5 or more segments) and / or risked (class II CPP)
- •which at least one measurable by RECIST (>2 cm, or >1 cm if Computed tomography (CT) spiraled)
- •Or extra-hepatic disease of small size potentially accessible to a resection (one or two lung metastases, lymphadenopathy localized accessible to curative resection)
- •colon or rectal primary tumor : resected or asymptomatic
- •Progression after first line chemotherapy to treat the metastatic disease, all types of treatment allowed except intra-arterial Bevacizumab
- •Age >18 years <75 years
- •Performance status WHO 0 or 1
- •Life expectancy >3 months
- •Bilirubin <1.5 times the upper limit of normal (N), ASAT and ALAT <5N, creatinine <1.5 N neutrophils >1.5 x 10^9/L, platelets ≥100 x 10^9/L, hemoglobin >9g/dL. Patients may be included even if they were transfused
- •CT (or MRI) reference for the measurement of metastases performed within 28 days before the first treatment cycle
- •Information of the patient or legal representative signing the informed consent
- •Affiliated to a social security system
排除标准
- •Symptomatic colon or rectal primary tumor (sub-occlusion, significant hemorrhage, major rectal syndrome)
- •Extra-hepatic metastases other than small size disease potentially accessible after resection
- •Grade 3-4 allergy to one of the treatment compounds
- •Two lines of prior chemotherapy. One line is allowed for metastatic disease but must have been started more than 6 months after completion of adjuvant treatment.
- •Participation during or within 30 days before study to another therapeutic trial with an experimental molecule
- •Concomitant cancer systemic treatment using immunotherapy, chemotherapy or hormone
- •Symptomatic CHD or myocardial infarction within 6 months prior entry into the study, cardiac arrhythmia uncontrolled despite treatment
- •Uncontrolled hypertension (blood pressure >150/100 mm Hg despite hypertensive treatment)
- •Heart Failure >Grade II of the New York Heart Association (NYHA) (class II-III-IV)severe renal failure
- •History and / or presence of bleeding disorders and/or thrombotic <6 months
- •Uncontrolled Serious illness, uncontrolled active infection or other serious underlying condition which may prevent the patient to receive treatment
- •Pregnancy (or positive pregnancy test at baseline), lactation or no contraception effective for men or women of childbearing age
- •Occlusion or sub-bowel obstruction or history of inflammatory bowel disease
- •Other cancer within 5 years prior to entry into the trial or concomitant (except in situ cancer of the cervix or skin basal-cell carcinoma properly treated)
- •Legal inability (persons deprived of liberty or under guardianship)
- •Inability to sign the consent or submit to medical test for geographical, social or psychological reasons.
研究组 & 干预措施
Patients with metastatic CRC
Experimental
干预措施: Bevacizumab (Drug)
Patients with metastatic CRC
Experimental
干预措施: Capecitabine (Drug)
Patients with metastatic CRC
Experimental
干预措施: Irinotecan (Drug)
结局指标
主要结局
Efficiency of treatment based on objective response rate
时间窗: Every 9 weeks from the start to tumoral progression
次要结局
- Treatment toxicity based on NCI-CTC v4.0(Every 3 weeks from the start to tumoral progression or toxicity preventing further processing)
- Progression Free Survival(Every 9 weeks form the start to tumoral progression)
- Hepatic metastasis resection rate(Assessed up 6 months after the end of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant ChemotherapyBevacizumabNeoadjuvant ChemotherapyMolecular Targeted TherapyBreast CancerNCT01652560LiNanlin,Ph.D, Chief Physician,Clinical Professor50
已完成
2 期
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal CancerHepatic MetastasesRectal CancerColon CancerNCT00200200Memorial Sloan Kettering Cancer Center73
已完成
不适用
Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT03170284Hoffmann-La Roche150
撤回
2 期
A Study of Bevacizumab to Prevent Malignant AscitesMalignant AscitesNCT00908219Baylor College of Medicine
Unknown
2 期
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid TumorLiver MetastasisNCT01511146Copenhagen University Hospital at Herlev100